Brought to you by 
Bioprocessing company Repligen raises $100mm in convertible notes
11 Aug 2016
Executive Summary
Repligen Corp. (bioprocessing for biologic drugs) raised $100mm in 2.125% redeemable (prior to June 5, 2019) convertible senior notes due 2021. Interest is payable semi-annually in arrears (each June 1 and December 1) beginning on December 1, 2016. The conversion rate is 31.1813 shares per $1,000 principal of the notes representing a conversion price of $32.07 per share.
Deal Industry
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bioprocessing company Repligen raises $100mm in convertible notes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice